Tumor Response Signature to Bevacizumab Recognized in HER2-Negative Breast Cancer
A collaborative team of researchers have been able to identify a gene signature that can predict how HER2-negative breast cancer patients would respond to treatment with bevacizumab.
NIH Approves Blueprint for Obama's Precision Medicine Initiative
The path to President Obama's Precision Medicine Initiative has been paved as is evident from a report released by a Working Group convened by the National Institutes of Health.
MAF Regulates Bone Metastases in Breast Cancer
Scientists in Spain have identified gene mutations that trigger bone metastasis in breast cancer patients.
The Cost Conundrum in Cancer Care
At the recently held NCCN healthcare policy summit in Washington, DC, experts delved into various models being evaluated to reduce healthcare utilization in oncology care.
An Open Discussion on Value in Oncology Care at the NCCN Policy Summit
Healthcare policy makers, payers, medical centers, and patient representatives shared the dais as they discussed The Value Proposition in oncology.
Bim Expression Could Predict Patient Response to PD-1 Blockade, Mayo Clinic Study Finds
Metastatic melanoma patients treated with pembrolizumab responded better if their T cells had a higher level of Bim expression.
In Conversation With an Oncologist: 340B and Its Impact on the Community
The American Journal of Managed Care spoke with Bruce J. Gould, MD, medical director of Northwest Georgia Oncology Centers on the impact of the 340B drug pricing program on private oncology practices.
Demographic Factors Influence Survival in Younger Patients With Leukemia
The study, published in the journal Cancer, found that non-biological factors are as important as biological variables in shaping outcomes in young patients with leukemia.
Care Access, Centers of Excellence, and the ACA: Expert Interchange at the NCCN Policy Summit
Healthcare policy experts gathered in Washington, DC, to discuss access, cost, and the definition of value in oncology care.
Reduced Adherence With Narrow Networks? CVS Says Otherwise
CVS Health says narrow networks improve medication adherence in patients with chronic diseases.
Immune Treatments in Cancer Need Additional Vigilance and Earlier Recognition
An abstract presented at the 16th World Conference on Lung Cancer presented results from a study that monitored irAEs resulting from treatment with immune checkpoint inhibitors.
Study Identifies Actionable Mutations in Young Lung Cancer Patients
Presented at the ongoing World Conference on Lung Cancer, the trial has identified 7 actionable genomic alterations in lung cancer patients under 40 years of age.
ASCO Submits Comments on the Proposed Medicare Physician Fee Schedule Rules
At the end of CMS' comment period, the American Society of Clinical Oncology submitted its comments and recommendations for the proposed changes.
CalPERS Successfully Implemented Reference Payment to Save on Colonoscopy Costs
The California Public Employees' Retirement System saved $7 million on screening colonoscopies during a 2-year period following implementation of reference pricing.
FDA Grants Priority Review for Alectinib in Advanced NSCLC Resistant to Crizotinib
The drug, approved in Japan last year, had been granted Breakthrough Therapy designation by the FDA.
Preliminary Results Promising for Opdivo-Yervoy as First-Line in Advanced NSCLC
With a new dosing schedule, low toxicity and a PD-L1 expression-driven response was observed.
CMS Changes to Physician Fee Schedule Face Resistance From Radiation Oncologists
With the comment period ending today, the proposed CMS cuts to radiation oncology reimbursement rates might have a substantial impact on community treatment centers.
Keytruda Gains NICE Approval While Kadcyla Fails
Cancer drug cost troubles in the UK prompt NHS to slash its list of approved-for-use oncology products.
Watch and Wait Feasible in Nearly 70% of Men With Prostate Cancer, Study Suggests
Urologists analyzing data from prostate cancer patients suggest wait and watch in well-informed low-risk prostate cancer patients.
Integrating Genomics into Pediatric Cancer Care
Study provides proof that a child's genetic makeup can provide actionable information to alter cancer treatment regimens.
Long-Anticipated Biosimilar From Novartis Launched, but at What Price?
Novartis has announced that Zarxio will be available at 15% of the cost of its reference product Neupogen.
Prophylactic Breast Surgery on the Rise in Men With Breast Cancer
Men are opting for preventive breast surgery when diagnosed with unilateral invasive disease, a study published in JAMA Surgery has found.
Telehealth Intervention Can Overcome Barriers to Colorectal Screening
Personalized telephone counseling and tailored educational materials can improve colonoscopy rates among at-risk family members of patients with colorectal cancer.
EHR Redesign Necessary for Efficient Care Delivery in Primary Care Clinics
A study evaluating EHRs has identified ways to make them more efficient for physicians, with the goal of improving patient care.
ASCO Publishes Policy Update on Genomic Testing for Cancer Susceptibility
The Cancer Prevention and Ethics Committees of the American Society of Clinical Oncology have made several recommendations that address genetic and genomic testing policies for cancer risk assessment.
Elotuzumab Accepted for Priority Review by FDA for Previously-Treated Patients With Multiple Myeloma
The submission by BMS includes results from the ELOQUENT-2 trial that were recently published in the New England Journal of Medicine.
Gene Signature Could Predict Development of Pancreatic Cancer, Allow Personalized Treatment
A novel microRNA gene signature could guide earlier intervention in pancreatic cancer.
ASCO Updates Guidelines for Advanced Lung Cancer
An expert panel of ASCO developed recommendations for advanced lung cancer treatment after reviewing published literature.
New 340B Draft Guidance May Increase Bureaucracy
The new guidance released by HRSA proposes to improve oversight over the drug pricing program.
Study Highlights Importance of Different-Hospital Readmission in Measuring Pediatric Care Quality
When measuring quality of pediatric care, hospitals should include different-hospital readmission along with same-hospital readmission, the authors conclude.
